Imagine Reducing the Time to Identify a Drug

April 28, 2022

Imagine Reducing the Time to Identify a Drug

Patients with mutated KRAS (Kirsten rat sarcoma virus) gene account for around 30-50% of the population with colorectal cancer (CRC) and do...

read more

Exclusive interview with Dr Carla Verissimo

November 10, 2021

Exclusive interview with Dr Carla Verissimo

Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview of the...

read more

EUROTOX 2021 | Poster 391

October 11, 2021

EUROTOX 2021 | Poster 391

Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen. Poster 391: Intestinal organoids as in vitro model...

read more

EUROTOX 2021 | Poster 553

October 6, 2021

EUROTOX 2021 | Poster 553

Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety. Poster 553: HUB Organoids™ improve preclinical toxicology, metabolism, and...

read more

2021 EUROTOX virtual congress

September 24, 2021

2021 EUROTOX virtual congress

HUB presents two posters at the 2021 EUROTOX virtuals congress. Meet the scientists behind the data. Wondering whether you should consider in...

read more

6th PREDiCT 3D Tissue Models

September 10, 2021

6th PREDiCT 3D Tissue Models

Meet our speaker Dr. Sylvia Boj discussing the next-gen models for complex disease modelling. Biopharma Pricing* - Register & Pay By Friday, February 11 & Save Up To...

read more

New PERSIST-SEQ program launched

September 2, 2021

New PERSIST-SEQ program launched

2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial leaders in...

read more

2021 Organoids are us

September 1, 2021

2021 Organoids are us

New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening, and patient stratification....

read more

Link revealed between HBV infection and liver cancer

August 31, 2021

Link revealed between HBV infection and liver cancer

HUB Organoids derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events that drive...

read more

New service partnership

August 18, 2021

New service partnership

VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for the use...

read more

CF models for drug development

August 12, 2021

CF models for drug development

HUB Organoids™ supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids™ advance treatment for...

read more

Test epithelial barrier function

August 5, 2021

Test epithelial barrier function

Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function has been...

read more

Model human diseases and select treatment

July 28, 2021

Model human diseases and select treatment

Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options. Classic in vitro disease...

read more

Model inflammation in a dish

July 27, 2021

Model inflammation in a dish

Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases. The lack of preclinical cellular...

read more

HUB at Innovation Parade

July 14, 2021

HUB at Innovation Parade

HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom of The...

read more

Personalized Health Basel

May 18, 2021

Personalized Health Basel

Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative. Personalized medicine holds great promise for the future of patient treatment, offering the...

read more

HUB and Yamaha for IVD

April 26, 2021

HUB and Yamaha for IVD

April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration to provide...

read more

Next-gen diagnostics

September 4, 2020

Next-gen diagnostics

Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they have signed a Memorandum of Understanding (MoU) to form a...

read more

Organoids for infectious disease

July 20, 2020

Organoids for infectious disease

HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease. During this virtual mini-symposium co-hosted with our partner STEMCELL...

read more

Ovarian cancer organoids

May 27, 2020

Ovarian cancer organoids

Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer...

read more

Understanding gut’s hormones

May 13, 2020

Understanding gut’s hormones

Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species of animals....

read more

SARS-CoV-2 infects gut cells

May 1, 2020

SARS-CoV-2 infects gut cells

Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have found that...

read more

A message from our CEO

April 1, 2020

A message from our CEO

Dear Valued Customer,On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. These are very...

read more

Organoids for genetic disorders

February 21, 2020

Organoids for genetic disorders

Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest CRISPR technology...

read more

HUB on Financial Times

December 10, 2019

HUB on Financial Times

On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer research".Prof. Clevers...

read more

PDX organoids in drug development

October 17, 2019

PDX organoids in drug development

San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform with the...

read more

Organoids-on-a-chip

October 1, 2019

Organoids-on-a-chip

Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to market organoid...

read more

Epistem license HUB Technology

July 16, 2019

Epistem license HUB Technology

Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in...

read more

HUB PDOs now at CrownBio

May 19, 2019

HUB PDOs now at CrownBio

San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology...

read more

New partner: CrownBio

April 9, 2019

New partner: CrownBio

March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a strategic partnership...

read more

New partner: Yamaha Motor

February 1, 2019

New partner: Yamaha Motor

February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide solutions that...

read more

X

Have any questions?

contact us